LAQV, REQUIMTE, Department of Chemistry, Faculty of Pharmacy, University of Porto, Rua de Jorge Viterbo Ferreira, 228, 4050-313 Porto, Portugal; Core of Medicine and Correlated Quality Control - NCQMC, Department of Pharmaceutical Sciences, Federal University of Pernambuco, Rua Arthur de Sá, s/n, Cidade Universitária, 50, 740-521 Recife, PE, Brazil.
LAQV, REQUIMTE, Department of Chemistry, Faculty of Pharmacy, University of Porto, Rua de Jorge Viterbo Ferreira, 228, 4050-313 Porto, Portugal.
Eur J Pharm Sci. 2018 Sep 15;122:22-30. doi: 10.1016/j.ejps.2018.06.017. Epub 2018 Jun 20.
An adapted methodology for obtaining lipid nanoparticles that only uses the microwave reactor in the synthesis process was developed. The method has the following features: one-pot, one-step, fast, practical, economical, safe, readiness of scaling-up, lack of organic solvents and production of nanoparticles with low polydispersity index (PDI) (below 0.3). This new method was applied for the development of nanostructured lipid carriers (NLC) loaded with a hydrophilic drug, the antiretroviral agent zidovudine (AZT). The aim of the present work was to develop, evaluate and compare optimized NLC formulations produced by two different methods - hot ultrasonication and microwave-assisted method. The development and optimization of the NLC formulations were supported by a Quality by Design (QbD) approach. All formulations were physicochemically characterized by the same parameters. The optimized formulations presented a suitable profile for oral administration (particle size between 100 and 300 nm, PDI < 0.3 and negative zeta potential >-20 mV). Furthermore, the morphologies assessed by TEM showed spherical shape and confirmed the results obtained by DLS. Both AZT loaded formulations were physically stable for at least 45 days and non-toxic on Jurkat T cells. Drug release studies showed a controlled release of AZT under gastric and plasma-simulated conditions.
开发了一种仅在合成过程中使用微波反应器即可获得脂质纳米粒的改良方法。该方法具有以下特点:一锅法、一步法、快速、实用、经济、安全、易于放大、无有机溶剂且生产的纳米粒具有低多分散指数(PDI)(低于 0.3)。该新方法应用于载有亲水性药物,即抗逆转录病毒药物齐多夫定(AZT)的纳米结构化脂质载体(NLC)的开发。本工作旨在开发、评估和比较两种不同方法(热超声和微波辅助法)制备的优化 NLC 制剂。NLC 制剂的开发和优化采用质量源于设计(QbD)方法。所有制剂均通过相同参数进行理化特性表征。优化的制剂具有适合口服给药的特性(粒径在 100 至 300nm 之间,PDI<0.3,负zeta 电位>-20mV)。此外,TEM 评估的形态显示出球形,证实了 DLS 获得的结果。两种载有 AZT 的制剂在至少 45 天内物理稳定,对 Jurkat T 细胞无毒。药物释放研究表明,在胃和血浆模拟条件下 AZT 可控制释放。